For research use only. Not for therapeutic Use.
Bifeprunox mesylate（Cat No.:I004245）is a synthetic compound that acts as a partial agonist at both dopamine D2 and serotonin 5-HT1A receptors. It is being studied primarily for its potential use in treating psychiatric disorders, particularly schizophrenia and mood disorders. Bifeprunox mesylate is thought to work by balancing dopamine and serotonin activity in the brain, which could improve symptoms of psychosis and mood instability. It has shown promise in preclinical and early-phase clinical trials, demonstrating potential as an atypical antipsychotic with fewer side effects compared to traditional antipsychotic medications. Further studies are needed to establish its safety and efficacy.
| Catalog Number | I004245 |
| CAS Number | 350992-13-1 (mesylate) |
| Synonyms | Bifeprunox; Bifeprunox Mesylate; DU-127090; DU 127090; DU127090.;7-(4-(Biphenyl-3-ylmethyl)piperazin-1-yl)benzoxazol-2(3H)-one methanesulfonate |
| Molecular Formula | C25H27N3O5S |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term or -20 °C for long term |
| IUPAC Name | methanesulfonic acid;7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one |
| InChI | InChI=1S/C24H23N3O2.CH4O3S/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19;1-5(2,3)4/h1-11,16H,12-15,17H2,(H,25,28);1H3,(H,2,3,4) |
| InChIKey | ONWKHSGOYGLGPO-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)O.C1CN(CCN1CC2=CC(=CC=C2)C3=CC=CC=C3)C4=CC=CC5=C4OC(=O)N5 |
| Reference | </br> 1: Chattopadhyay A, Frey S, Green G, Harkness A, McDermott A, Yates A. Bifeprunox vs Placebo for Schizophrenia. Schizophr Bull. 2016 Jul;42(4):881-2. doi: 10.1093/schbul/sbw048. Epub 2016 May 6. PubMed PMID: 27153863; PubMed Central PMCID: PMC490306 |
